Home › Funds › MPM BioImpact LLC › TSHA
MPM BioImpact LLC position in TSHA
TAYSHA GENE THERAPIES INC · Health Care
MPM BioImpact LLC reported holding 4,500,000 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q2 2026 13F filing — a position valued at US$30.6M, representing 1.87% of its reported portfolio and ranking #21 among its reported holdings. MPM BioImpact LLC has disclosed TSHA holdings in 2 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's TSHA position evolved
MPM BioImpact LLC first disclosed a stake in TSHA in Q2 2025 at 2,953,562 shares (US$6.8M). The position peaked in Q2 2026 at 4,500,000 shares, worth US$30.6M. Across 2 filings, MPM BioImpact LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 4,500,000 shares valued at US$30.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 2.95M | $6.82M | New |
| Q2 2026 | 4.50M | $30.64M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TSHA and 13F data
TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 56 other funds we track also report a position in TSHA — the largest reported positions include Avoro Capital Advisors LLC (US$162.7M), RA CAPITAL MANAGEMENT, L.P. (US$160.4M), Vestal Point Capital, LP (US$132.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TSHA
- Avoro Capital Advisors LLC 23.89M sh · $162.68M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 23.56M sh · $160.41M · Q2 2026
- Vestal Point Capital, LP 19.41M sh · $132.22M · Q2 2026
- RTW INVESTMENTS, LP 13.56M sh · $92.35M · Q2 2026
- Siren, L.L.C. 9.85M sh · $67.06M · Q2 2026
- Octagon Capital Advisors LP 9.69M sh · $66.01M · Q2 2026
- BAKER BROS. ADVISORS LP 4.00M sh · $27.27M · Q2 2026
- GordonMD Global Investments LP 723.18K sh · $24.50M · Q2 2026
- Casdin Capital 3.25M sh · $22.13M · Q2 2026
- ADAR1 Capital Management, LLC 3.04M sh · $20.71M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 1.99M sh · $13.57M · Q2 2026
- B Group, Inc. 1.80M sh · $12.26M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held TSHA?
MPM BioImpact LLC has disclosed TSHA holdings in 2 of the last 5 reported quarters, going back to Q2 2025.
What is MPM BioImpact LLC's current position in TSHA?
As of Q2 2026, MPM BioImpact LLC holds 4.50M shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $30.64M, representing 1.87% of its reported portfolio and ranking #21.
Has MPM BioImpact LLC been buying or selling TSHA?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC newly opened its position in TSHA. The position peaked in Q2 2026 at 4.50M shares.
Which other funds hold TSHA?
Other major institutional holders of TSHA include Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., Vestal Point Capital, LP, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.